AiCuris seeks partner for Phase III of HCV prophylactic
This article was originally published in Scrip
Executive Summary
As it presented positive Phase IIb results for letermovir (AIC246) for the prophylaxis of human cytomegalovirus (HCV) in recipients of human blood precursor cell transplants, German firm AiCuris said it is seeking a partner to progress the drug to Phase III.